| Hologic MammoSite ML radiation therapy approved | Posted on 07/09/2009 in Scientific Hologic has revealed that its radiation therapy system for the treatment of those with early-stage breast cancer has been approved by the Food and Drug Administration (FDA).
The product gives oncologists the flexibility to devise the correct dose of radiation with its multi-lumen design, which is ideal for patients who are not appropriate candidates to receive traditional brachytherapy.
It is also a commonly-used form of accelerated partial breast irradiation and has so far been used to treat more than 500,000 cancer patients in the US alone.
"With FDA clearance of the MammoSite ML radiation therapy system, we are now able to provide surgeons and radiation oncologists with a device designed to both maximise patient comfort and enable greater physician flexibility," commented David Harding, senior vice-president of Hologic's interventional breast solutions business.
Last month, Hologic revealed that a study on the impact of fetal fibronectin testing among both symptomatic and asymptomatic pregnant women at risk for preterm birth found that it has the potential to improve risk assessment and affect treatment decisions.
 Other news stories from 07/09/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
